Ta strona korzysta z plików cookie. Kontynuując przeglądanie strony zgadzasz się na używanie plików cookie.
Więcej informacji zamieszczono w naszej Polityce prywatności.×

PRZYPISY

Das S, Gupta PK, Das RR. Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country. J Trop Pediatr. 2016 Dec;62(6):464-470. Epub 2016 Jun 9.

Burande MA. Comparison of efficacy of Saccharomyces boulardii strain in the treatment of acute diarrhea in children: A prospective, single-blind, randomized controlled clinical trial. J Pharmacol Pharmacother. 2013 Jul;4(3):205-8

Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005 Mar 1;21(5):583-90

Billoo A, Memon M, Khaskheli S, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World Journal of Gastroenterology: WJG. 2006;12(28):4557-4560

Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, Vandenplas Y. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007 Apr;96(4):538-41

McFarland LV, Surawicz CM, Greenberg RN, et al.A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-191.

H.Kollarisch & al. Prevention of traveller’s diarrhea: Comparison of different non-antibiotic preparations. Travel Medecine International. 1989: 9-17.

Kollaritsch H , Holst H, Grobara P, Wiedermann G. [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med. 1993 Mar 30;111(9):152-6.

Mansour-Ghanaei F, Shafaghi A, Fallah M. The effect of metronidazole in treating human fascioliasis. Med Sci Monit. 2003 Oct;9(10):PI127-30.

Moré M, Swidsinski A.; Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review.; Clin Exp Gastroenterol. 2015; 8: 237–255.

McFarland LV, Systematic review and meta-analysis of Saccharomyces Boulardii in adults patients, World J Gastroenterol 2010 May 14; 16(18): 2202-2222

Na podstawie wyników uzyskanych podczas przeglądu bazy PubMed, stan na czerwiec 2018

Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z; Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506.

WGO; Probiotics and prebiotics; February 2017.

Sender R, et al. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016; 14(8): e1002533.

D’Argenio V and Salvatore F. The role of the gut microbiome in the healthy adult status. Clinica Chimica Acta, 2015; 451: 97-102.

Tojo R, et al. Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014; 20(41): 15163-15176.

Tanaka M and Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Al/ergo/1111. 2017 Aug 17.doi: 10.1016/j.alit.2017.07.01O. [Publikacja elektroniczna].

Mulak A and Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015; 21(37): 10609–10620.

Mulle JG. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep. 2013; 15(2): 337.

Rogers GB. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry. 2016; 21: 738-748.

Schaubeck M. Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016; 65(2): 225-37.

Sheflin AM, et al. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. Curr Oncol Rep. 2014; 16(10): 406.

SZAJEWSKA H., PROBIOTYKI W POLSCE — KIEDY, JAKIE I DLACZEGO? GASTROENTEROLOGIA KLINICZNA 2010, TOM 2, NR 1, 1–9.

Gerritsen J. et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011; 6(3): 209-240.

D’Argenio V and Salvatore F. The role of the gut microbiome in the healthy adult status. Clinica ClinicaActa. 2015;451:97-102.

Hawrelak JA and Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev. 2004; 9(2): 180-97.

Gomez Gallego C and Salminen S. Novel probiotics and prebiotics: how can they help in human gut microbiota dysbiosis. Appl Food Biotechnol. 2016;3(2): 72-81.

Tanaka M and Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017 Aug 7.doi:10.1016/j.alit.2017.07.010. [Publikacja elektroniczna].

Bull MJ and Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. lntegrative Medicine: A Clinician’s Journal. 2014;13(6):17-22.

Brubaker L and Wolfe AJ. The female urinary microbiota, urinary health and common urinary disorders. Ann Transl Med. 2017: 5(2):34.effects of microbial dysbiosis. Curr Oncol Rep. Curr Oncol Rep. 2014; 16(10): 406.

World Health Organization, Food and Agricultural Organization of the United Nations. Health and nutritional properties of probiotcs in food including powder milk with live lactic acid and bacteria. FAO Nutrition Paper, 2001;85.

Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008; 46(Suppl 2): S58-61.